Benzinga - by Vandana Singh, Benzinga Editor.
Thursday, Genentech, a unit of Roche Holdings AG (OTC:RHHBY), released results from the Phase 1b trial of CT-388, a dual GLP-1/GIP receptor agonist being developed for the treatment of obesity and type 2 diabetes.
The study found that a once-weekly subcutaneous injection of CT-388 over 24 weeks resulted in significant weight loss in healthy adults with obesity compared to placebo.
The weight loss achieved with CT-388 was clinically meaningful, with a mean placebo-adjusted weight loss of 18.8% (p-value
At week 24, 100% of CT-388 treated participants achieved a weight loss of over 5%, 85% achieved over 10%, 70% achieved over 15%, and 45% achieved over 20%.
The treatment was well tolerated, with mild to moderate gastrointestinal-related adverse events being the most common, consistent with the incretin class of medicines that CT-388 belongs to.
All participants with a pre-diabetes status at baseline became normoglycemic after 24 weeks of CT-388 treatment, whereas the glycemic status of participants treated with placebo remained largely unchanged during this period.
CT-388 belongs to the class of incretin-based medicines that aim to regulate blood sugar and reduce appetite.
It selectively targets and activates two specific receptors in the body, GLP-1 and GIP, which integrate nutrient-derived signals to control food intake, energy absorption and assimilation.
An additional cohort from the ongoing placebo-controlled Phase 1b trial of CT-388 will evaluate obese patients (BMI>30 kg/m2) with type 2 diabetes over a 12-week treatment duration.
Roche expects data from this additional cohort in the second half of 2024.
In December, Roche agreed to acquire a privately held obesity company, Carmot Therapeutics, for $2.7 billion in cash. Additionally, Carmot’s equity holders are entitled to receive payments of up to $400 million depending on achieving certain milestones.
Once-a-week injection CT-388 is Carmot’s obesity candidate.
Photo by Vidmir Rais via Pixabay
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.